CONNECTA_Therapeutics Initiates CTH120 Phase IIa Trial

CONNECTA Therapeutics>>>, a clinical-stage biotech company, announced the initiation of its Phase IIa clinical trial for CTH120, a first-in-class neuroplasticity modulator, in adult males with Fragile X syndrome>>>. This study builds on positive Phase I safety data and aims to evaluate the safety, tolerability, pharmacokinetics, and clinical efficacy of CTH120>>>. The trial is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study involving 30 adult males aged 18-45. It is being conducted at Hospital del Mar Research Institute>>> and Institute for Research and Innovation Parc Taulí>>> in Spain, with leadership from Rafael de la Torre Fornell>>>. The Centre for Genomic Regulation>>> will also contribute to biomarker identification. The study has been authorized by the Spain — Spanish Agency of Medicines and Medical Devices>>> and is funded by the Spain — Ministry of Science, Innovation and Universities (Spain)>>> and the European Union>>>'s NextGeneration EU program. This represents a key milestone for CONNECTA Therapeutics>>> and offers a potentially disease-modifying approach for Fragile X syndrome>>>, a condition with no approved targeted therapies.